Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
17 Apr 24
8-K
Regulation FD Disclosure
27 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8 Mar 24
424B3
Prospectus supplement
16 Feb 24
8-K
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
16 Feb 24
EFFECT
Notice of effectiveness
24 Jan 24
CORRESP
Correspondence with SEC
22 Jan 24
UPLOAD
Letter from SEC
19 Jan 24
S-8
Registration of securities for employees
11 Jan 24
S-3
Shelf registration
10 Jan 24
8-K
Departure of Directors or Certain Officers
5 Dec 23
8-K
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
27 Nov 23
S-8
Registration of securities for employees
20 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
13 Nov 23
8-K
Ocuphire Corporate Presentation November 2023
2 Nov 23
8-K
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
1 Nov 23
8-K
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
27 Sep 23
424B5
Prospectus supplement for primary offering
14 Aug 23
8-K
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
1 Aug 23
UPLOAD
Letter from SEC
12 Jul 23
CORRESP
Correspondence with SEC
7 Jul 23
UPLOAD
Letter from SEC
28 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
2 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
15 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEF 14A
Definitive proxy
1 May 23
8-K
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
21 Apr 23
S-8
Registration of securities for employees
5 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
30 Mar 23
8-K
Regulation FD Disclosure
25 Jan 23
8-K
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
6 Dec 22
8-K
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
7 Nov 22
Latest ownership filings
4
Jay Pepose
15 Apr 24
4
JOSEPH K SCHACHLE
25 Mar 24
4
Nirav S. Jhaveri
25 Mar 24
4
George Magrath
20 Mar 24
4
Nirav S. Jhaveri
14 Feb 24
4
Ashwath Jayagopal
14 Feb 24
3
Nirav S. Jhaveri
14 Feb 24
3
Ashwath Jayagopal
14 Feb 24
4
Bernhard Hoffmann
22 Jan 24
4
Rabourn Amy Zaremba
22 Jan 24
4
Rabourn Amy Zaremba
12 Jan 24
4
Ronil A. Patel
12 Jan 24
4
Bernhard Hoffmann
12 Jan 24
4
Jay Pepose
3 Jan 24
4
JAMES S J MANUSO
3 Jan 24
4
Richard J Rodgers
3 Jan 24
4
Susan Benton
3 Jan 24
4
Ronil A. Patel
5 Dec 23
4
JOSEPH K SCHACHLE
27 Nov 23
3
JOSEPH K SCHACHLE
27 Nov 23
4
Jay Pepose
13 Nov 23
4
Richard J Rodgers
13 Nov 23
4
George Magrath
3 Nov 23
3
George Magrath
3 Nov 23
4
Sean Ainsworth
8 Jun 23
4
JAMES S J MANUSO
8 Jun 23
4
Jay Pepose
8 Jun 23
4
Susan Benton
8 Jun 23
4
Cam Gallagher
8 Jun 23
4
Ronil A. Patel
26 Apr 23
3
Ronil A. Patel
26 Apr 23
4
JAMES S J MANUSO
21 Apr 23
4
Susan Benton
21 Apr 23
4
Richard J Rodgers
21 Apr 23
4
Jay Pepose
21 Apr 23
SC 13G/A
Sooch Mina
14 Feb 23
5
Mina Sooch
14 Feb 23
5
Sean Ainsworth
14 Feb 23
4
Mina Sooch
12 Jan 23
4
JAMES S J MANUSO
12 Jan 23